pantoprazole has been researched along with Obesity in 7 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 9.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 7.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "Overweight/obesity in GORD patients does not appear to affect the antisecretory efficacy of a single dose of rabeprazole and pantoprazole." | 5.17 | On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? ( Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013) |
| "A total of 200 overweight or obese patients with RE-AB were evenly randomized into a double-dosed group (receiving 8-week pantoprazole 40 mg twice daily) or a standard-dosed control group (receiving 8-week pantoprazole 40 mg per day and one blank tablet at night)." | 5.14 | Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. ( Chang, WL; Chen, WY; Cheng, HC; Lu, CC; Sheu, BS; Tsai, YC, 2010) |
| " In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers." | 3.88 | A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. ( Brian Smith, P; Cohen-Wolkowiez, M; Collier, DN; Guptill, JT; James, LP; Kearns, GL; Livingston, CE; Shakhnovich, V; Wu, H; Zhao, J, 2018) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 3.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shakhnovich, V | 2 |
| Smith, PB | 1 |
| Wu, H | 2 |
| Cohen-Wolkowiez, M | 2 |
| Kearns, GL | 2 |
| Friesen, JHP | 1 |
| Brian Smith, P | 1 |
| Guptill, JT | 1 |
| James, LP | 1 |
| Collier, DN | 1 |
| Livingston, CE | 1 |
| Zhao, J | 1 |
| Bruley des Varannes, S | 1 |
| Coudsy, B | 1 |
| Waechter, S | 1 |
| Delemos, B | 1 |
| Xiang, J | 1 |
| Lococo, J | 1 |
| Ducrotté, P | 1 |
| Chen, WY | 1 |
| Chang, WL | 1 |
| Tsai, YC | 1 |
| Cheng, HC | 1 |
| Lu, CC | 1 |
| Sheu, BS | 1 |
| Brigas, D | 1 |
| Kindt, S | 1 |
| Imschoot, J | 1 |
| Tack, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pantoprazole and Obesity
| Article | Year |
|---|---|
On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2013 |
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Body Mass Index; Dose-Response Relationship, D | 2010 |
5 other studies available for pantoprazole and Obesity
| Article | Year |
|---|---|
Reply.
Topics: Body Weight; Child; Humans; Obesity; Pantoprazole | 2018 |
Pantoprazole pharmacokinetics in obese children: normalized to lean or ideal weight?
Topics: Body Weight; Child; Humans; Obesity; Pantoprazole | 2018 |
A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Area Under Curve; Body We | 2018 |
Gastro-oesophageal reflux disease in an obese patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastroesoph | 2009 |
Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alcoholism; Anorexia; Anti-Inflammatory Agents | 2011 |